Clinical Data

Karyopharm

Pharma

Karyopharm reports Xpovio miss, FDA filing in separate cancers

Reporting a new miss in one cancer indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another.

Fraiser Kansteiner Jul 31, 2026 10:00am

photo of a pair of hands that show the skin condition vitiligo

Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie

Jul 30, 2026 2:15pm

AZ leans on cancer, rare disease muscle in solid Q2

Jul 27, 2026 10:21am

Tavneos

Amgen submits analyses to FDA in bid for Tavneos hearing

Jul 24, 2026 10:50am

hair hair loss baldness female pattern hair loss

Veradermics reports ph. 2 win in female pattern hair loss

Jul 15, 2026 11:27am

arrow miss target fail attempt try

BMS details Krazati confirmatory fail in colorectal cancer

Jul 7, 2026 10:46am